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Summary
In December 2010, a workshop was held at “Regi-
na Elena” National Cancer Institute in Rome, Italy,
to develop an update on GH/IGF-1 system. The
workshop was supported by NoGeRo group and
was sponsored by SIE Lazio (Società Italiana di
Endocrinologia-Lazio Regional Section) and AME
Lazio (Associazione Medici Endocrinologi-Lazio
Regional Section). Invited participants included
italian endocrinologists skilled in the field of GH
and IGF-I system both in basic and clinical re-
search. In the following two years an extensive re-
view has been structured summarizing the most
important points achieved in the discussions dur-
ing the workshop.
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Introduction
GH/IGF-I axis
The GH/IGF-I system comprises of several proteins
controlling growth, metabolism and senescence. Once
thought to act predominantly through direct effects, it is
now clear that the GH/IGF-I system can influence nu-
merous cellular processes via indirect effects on the
signaling machinery. From a hierarchical point of view,
many growth-promoting actions of this system imply an
adequate secretion of GH, a 191 aminoacid single
chain polypeptide hormone with 2 disulphide bridges
originating from somato (mammo) troph cells located in
the lateral sections of the pituitary, where GH is stored
in granules of 350-500 nm (1). Five homologous genes
exist in the GH locus, a 66 kb region of DNA located in
chromosome 17q22-q24. In the circulation, the preva-
lent GH isoform is of 22 kDa (~73%), while less preva-
lent is the 20 kDa isoform (~16%) as well as alternative
isoforms (~10%). Spontaneous GH secretion is typical-
ly pulsatile and peaks every 60-90 min. It increases dur-
ing the sleep, particularly during the stage 3-4. GH se-
cretion is high in the fetal stage, decreases in the
neonatal stage, then spontaneous peaks are more fre-
quent and intense in pediatric age. Subsequently, it is
calculated that GH production is 100 mcg/24 hr in the
prepuberal stage, 700 mcg/24 hr in adolescents and
400 mcg/24 hr in adults. Elderly individuals harbor the
lowest levels of GH and this condition has been termed
somatopause. GH yields a 20-40 min half-life if admin-
istered intravenously and a 12-24 hr half-life if adminis-
tered intramuscularly. The regulatory mechanisms of
GH secretion are sexually dimorphic, with men having
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larger nocturnal GH pulses and relatively smaller puls-
es at daytime compared to women, who show more
continuous and uniform GH pulses. On the other hand,
rh-IGF-I administration causes a more potent feedback
on spontaneous and GHRH-induced GH secretion in
men than women, suggesting in the latter a stronger in-
tervention on hypothalamic GHRH on the negative reg-
ulation of GH secretion (2). Several factors are known
to influence the secretion of GH. Among these, GHRH
and somatostatin act as the chief neuroendocrine stim-
ulator and suppressor, respectively, while the physio-
logical role of ghrelin on GH stimulation needs further
elucidation. It is worth mentioning the stimulatory effect
of exercise, stress, aminoacids, muscarinic cholinergic
and alpha-adrenergic tone, glucocorticoids (acutely),
opioid peptides, L-arginine and hypoglycaemia. Oppo-
sitely, beta-adrenergic tone, glucocorticoids (chronical-
ly), obesity, malnutrition and hyperglycaemia all are
negative regulators of GH secretion (3). The peripheral
effects of GH include multiple actions on: bone metab-
olism, by increasing osteoclast differentiation and activ-
ity, osteoblast activity, bone mass and endochondral
bone formation; linear growth, where GH promotes epi-
physeal growth (this is also known as the “dual effector”
theory), stimulates the differentiation of prechondro-
cytes and the local expression of IGF-I, which then in-
creases clonal expansion of chondrocytes; muscle
mass, through effects on amino acid transport, nitrogen
retention, lean tissue formation and energy expendi-
ture; adipose tissue, by increased lipolysis, inhibited
lipoprotein lipase, stimulated hormone sensitive lipase,
decreased glucose transport, decreased lipogenesis
(4). The cellular actions of GH are mediated by a trans-
membrane receptor (GHR) of 620 aminoacids that be-
longs to the type-1 cytokine receptor family; the extra-
cellular domain also works as the circulating GH bind-
ing protein, and retains diagnostic significance in the
GH-resistance setting (5). In the cell, GH action is me-
diated by multiple signaling cascades, the most rele-
vant of which is the JAK-STAT pathway (6). Mutations
in the GHR gene provoke a condition of GH resistance:
over 600 mutations have been identified and all lead to
Laron’s syndrome, a condition of IGF-I deficiency, short
stature and typical somatic features. In addition to the
previous, it has become clear that postreceptor muta-
tions, particularly those involving Stat 5-b, can also
cause GH resistance. In such settings, treatment with
rh-IGF-I is approved as the only effective therapeutic
tool to compensate for the hormone loss (6). Once
known as the peripheral effector of GH, it is now evident
that IGF-I not only is GH-dependently and -independ-
ently involved in controlling growth but it also controls
cell proliferation. IGF-I is a basic polypeptide of 70
amino acids (M.W. ~ 7600 d), formed by two chains
linked by a connecting peptide. The liver produces >
80% of the circulating peptide, however IGF-I is ex-
pressed and synthesized in multiple tissues where it
acts to govern local cellularity and metabolism via au-
tocrine and paracrine actions. It circulates as a single
non-glycosylated chain with two disulfide bridges, and a
50% amino acid sequence homology to insulin explains
its ability to bind to insulin receptors and insulin-IGF-1
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hybrid receptors, thereby also acting at the metabolic
level with insulin-like properties. IGF-I shares ~60% se-
quence homology to IGF-II. IGF-I levels are influenced
by multiple factors, with GH being the most relevant.
Among the other contributors, also important are the
genetic environment, nutrional state, sex hormones,
IGFBPs, insulin, thyroid hormones, cortisol, immune
system and catabolic states (7). IGF-I levels increase
gradually from childhood and reach their peak concen-
tration at puberty, then they decrease gradually. In the
circulation, IGF-I is associated with ALS and IGFBP-3 in
a ~150kDa complex that works as a reservoir of IGF-I
and contributes to regulate its bioactivity and half-life.
All components of this ternary complex are regulated by
GH. Moreover, IGF-I and IGFBP-3 can form binary
complexes, that are active locally. As mentioned above,
recent evidences indicate that GH and IGF-I roles on
growth are partly independent. It has been estimated
that growth processes in mammals depend for ~34% on
a their combined action, for ~14% on GH alone, for
~35% on IGF-I alone and for ~17% on other factors (8).
Recent data further suggest that IGF-I can amplify the
metabolic actions of GH and contrast its deleterious ef-
fects on lipolysis, gluconeogenesis and insulin-resist-
ance (9). Indeed, many cellular actions of IGF-I are pro-
liferative and antiapoptotic in several organs and appa-
ratuses. One central player in the prevention of cell
death is the IGF-I receptor (IGF-IR). Transduction of
signals through this receptor leads to multiple series of
intracellular phosphorylation events and the activation
of several signaling pathways. The IGF-IR consists of
two disulphide-linked αβ heterodimers and it is struc-
turally similar to the insulin receptor (10). Both IGF-I
and IGF-II bind the IGF-I receptor with high affinity and
insulin binds with lower affinity. Upon ligand binding, the
receptor has tyrosine kinase activity resulting in au-
tophosphorylation, recruitment of docking proteins such
as IRS-1 and subsequent stimulation of many signal
transduction pathways, including Ras/MAP (mitogen-
activated protein) kinase, PI3 kinase/PKB (protein ki-
nase B) Akt and PI3 kinase/mTOR. These pathways
convey mitogenic and metabolic signals and certain ef-
fects of insulin and IGFs can be limited by drugs or nu-
tritional conditions that alter AMPK (AMP-activated pro-
tein kinase) signalling or mTOR signaling. Mechanisms
of IGF system signaling that prevent cell death contin-
ue to be identified, suggesting that cells have alterna-
tive ways to avert death signals in addition to primary
protective pathways. While the IGF-I receptor is virtual-
ly ubiquitous in humans, its density appears to differ
from one tissue to another. However, IGF-IR activation
by IGF-I delivered to the cell by endocrine, autocrine or
paracrine modalities, is accompanied with relevant ac-
tions on immediate early gene expression, stimulation
of myogenesis, apoptosis, cell cycle progression, im-
mune response modulation, induction of enzymes in-
volved in steroidogenesis, and sex steroid production
(11). Actions on cell survival involve increased activity
of antiapoptotic factors (through modulation of p53, NF-
κB, Bcl-2 expression) and inhibition of proapoptotic fac-
tors (through modulation of caspases and Bad) (10).
The IGF-II/mannose 6-phosphate (M6P) receptor is
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structurally distinct from IGF-I and insulin receptors, it
binds IGF-II with high affinity, IGF-I with far lower affini-
ty and does not bind insulin. Its major IGF-related role
appears to be IGF-II internalisation and clearance. A
soluble form of this receptor which lacks the transmem-
brane and intracellular domains is found in the circula-
tion. It should be mentioned that IGF-I genotyping has
revealed a role for IGF-I mutations in cardiovascular
disease, while mutations in the IGF-IR gene may retard
intrauterine and subsequent growth in humans (12).
The GH/IGF system is thus relevant in many physiolog-
ical and pathophysiological conditions. The direct in-
volvement of IGF-I in human diseases like GH-related
disorders, cancer, atherosclerosis, diabetes, osteoporo-
sis and neuromuscular disorders has prompted exten-
sive research for therapeutic purposes. A better under-
standing of the system may enable to elaborate on lig-
and- and tissue-specific IGF-based therapies without
interfering with physiological processes. Additionally,
their role in the diagnosis and monitoring of diseases
should be better clarified in the near future.
IGF-binding proteins (IGFBPs)
The IGF system, besides the two growth factors IGF-
I and IGF-II, the cell surface receptors, IGF-IR and
IGF-IIR, comprises six specific high-affinity binding
proteins (IGFBP-1 to IGFBP-6), as well as the IGFBP
proteases, that regulate and propagate IGF actions in
several tissues (13). Hepatic IGF-I circulates almost
entirely (> 99%) bound to IGFBPs. IGFBP-3, a major
IGFBP type in circulation, binds 75 to 90% of circulat-
ing IGF-I in a large ternary complex consisting of IGF-
BP-3, acid-labile subunit (ALS), and IGF (150 kDa). It
is still debated whether IGFBP-3 in the liver is posi-
tively regulated upon GH stimulation or regulation of
circulating IGFBP-3 in human subjects is due to in-
creased formation of the ternary complex induced by
GH (14,15). ALS is produced in the liver as a direct ef-
fect of GH. The ALS stabilizes the IGF-IGFBP-3 com-
plex, reduces the passage of IGF-I to the extravascu-
lar compartment, and extends its half-life (13). More
recently it has become clear that IGFBPs 1-6 have in-
trinsic biological activity (IGF/IGF-IR-independent ac-
tions) in addition to their actions to bind IGFs and se-
quester the active hormone. In particular, IGF/IGF-IR-
independent actions of IGFBP-3 (antiproliferative and
proapoptotic effects) seem to contribute in improving
the pathophysiology of a variety of human diseases,
such as cancer, diabetes, and malnutrition (16). Nine
other forms of IGFBPs, which have low affinity for
IGFs, have been identified due to their high homolo-
gy in gene sequences with those of IGFBP 1-6 (17).
These carrier proteins, whose role is currently under
study, were grouped in a family defined as IGFBP re-
lated proteins (IGFBP-RP) (17). The binary complex-
es of 40-50 kDa, carrying 20-30% of IGF-I and II, are
composed primarily of IGFBP-2. Plasma concentra-
tions of IGFBP range from 5-50 ng/ml of IGFBP-1 and
100-400 ng/ml of IGFBP-2 to 2-4 mg/ml of IGFBP-3,
confirming the greater significance as carrier protein
in circulation if this latter BP (17). Although the mech-
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anisms by which IGF complexes becomes available
for binding with receptors in tissues are not yet fully
understood, several studies have highlighted the ex-
istence of plasma and tissue specific proteases for
IGFBPs, able to facilitate the process of dissociation
from IGFBPs (13, 17). Several proteases specific for
each IGFBP have been identified so far. Among
these, metallo-proteases degrading IGFBP-3 are the
best characterized, and are often serine proteases
metal- and calcium-dependent (PSA, γ-NGF, plasmin
metallo-proteases MMP-1, -2 and -3 are part of this
group). Beside the key role in growth and differentia-
tion, there is now compelling evidence to suggest that
members of the IGFBP family play important roles in
metabolic homeostasis. For example, IGFBP-1 con-
centrations fluctuate inversely in response to changes
in plasma insulin levels, implicating IGFBP-1 in glu-
coregulation, and fasting levels of IGFBP-1 predict in-
sulin sensitivity at the population level, whereas IGF-
BP-2 concentrations reflect long-term insulin sensitiv-
ity and are reduced in the presence of obesity (18).
Accumulating evidence indicates that abnormalities
of IGF-I and IGFBP-1 occur in insulin-resistant states
and may be significant in the pathophysiology of type
2 diabetes, as well as in the development of cardio-
vascular disease in metabolic disorders, including di-
abetes and obesity (19). These evidences are prom-
ising for future therapeutic strategies, because,
based on the potential vasculoprotective effects of
both IGF-I and IGFBP-1, the system represents an in-
teresting and novel therapeutic target in the preven-
tion of cardiovascular disease in type 2 diabetes.
Moreover, progress on the metabolic-related function
of IGFBPs has indicated the close relation between
IGFBPs and the components of the metabolic syn-
drome. Indeed, abnormal expression of IGFBP has
been detected in various states of the metabolic dis-
orders, suggesting that it could be also used as a
convenient and sensitive marker of insulin resistance,
identification of insulin-resistant individuals at high
cardiovascular risk, and may be an earlier marker of
the metabolic syndrome (20). Bone metabolism rep-
resent another important target since the 6 IGFBPs
are expressed by osteoblasts. However the principal
actor in this setting seems IGFBP-2, which is required
for normal bone formation in mice and seems also in-
volved in bone remodeling (21). Conversely, the role
of the other IGFBPs in bone homeostasis is still con-
troversial, although it appears that their fundamental
role is to bind and serve as transporters/regulators of
IGF-I in this site as well (21, 22). Indeed, as already
emphasized, IGFBPs can have both enhancing and
inhibiting effects on IGF action, depending on context
and posttranslational modifications. The IGF pathway
has been shown to be activated in many cancer types
(23). IGF binds to two types of receptors, IGF-IR and
IGF-IIR, on cell membranes, and activates the tyro-
sine kinase pathway downstream. Binding of IGFBPs
with IGF has been shown to either positively or nega-
tively regulate the binding of IGFs to their receptors,
thus directly affecting the IGF signaling pathways.
However, several studies have found that IGFBPs
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may also function independently, interacting with pro-
teins other than IGFs, may be cleaved, may bind to
their own receptor on the membrane (13, 14). Impor-
tantly, there is increasing evidence that IGFBP-2,
IGFBP-3, and IGFBP-5 are important players in the
phenotypes of various cancers (23). Changes in the
balance of the components of the IGF system may
contribute to the progression of cancer (23, 24). The
levels of IGFBPs have been associated with reduced
risk for prostate, breast and other cancers (23, 24).
Experimental studies have implicated high levels of
IGF-I directly and IGFBP-3 inversely in prostate can-
cer growth, survival, and progression. In the Euro-
pean Prospective Investigation into Cancer and Nutri-
tion (EPIC) study, high circulating IGF-1 concentra-
tion was positively associated with risk for prostate
cancer (25). However, other evidences suggest a
much weaker association of IGF-I with prostate can-
cer development and a stronger antagonistic associ-
ation of IGFBP-3 with prostate cancer progression
(26). Considering the clonal heterogeneity and unpre-
dictable progression pattern of prostate cancer, the
role of any single growth factor or its regulator, includ-
ing IGFBP, as a single determining factor is limited. In
breast tumors the abundance of IGFBPs relates to
the estrogen receptor status and their production in
the breast is controlled by hormones, principally es-
trogen and progesterone (27). However, also in this
setting there conflicting observations between the ef-
fects of IGFBPs on the risk of cancer development, in
particular IGFBP-3 (27). Indeed, the functional activi-
ty of IGFBPs can also be affected by proteolysis,
phosphorylation and glycosylation and the implica-
tions of these determinants are still unclear so far. In
general, the IGFs in certain tissues are present at lev-
els far in excess of that required for maximal receptor
stimulation, and the IGFBPs are critical regulators of
their cellular actions. Beside this action, IGF-inde-
pendent BPs effects on cell functions is still contro-
versial. For example, again in breast, locally IGF
bioactivity is influenced not only by tissue expression
and regulation of IGFs, IGFBPs and IGFBP proteas-
es, but also by other factors delivered from the circu-
lation (23, 24). As prognostic values, only IGFBP-3
may serve as an important factor in evaluating cancer
risk, in prognosis and, in the future, as a treatment as
well. Although epidemiological studies vary in their
conclusions about IGFBP-3 and reduced cancer risk,
many population variables and assay problems may
contribute to this lack of uniformity. Since IGFBP-3 is
a highly effective proapoptotic factor in tumor cells by
a variety of mechanisms, therapy directly with exoge-
nous IGFBP-3 or indirectly with hormonal or other up-
regulators of IGFBP-3 may be an important mode of
cancer therapy in the future (16). Recent evidence
suggests that high serum IGFBP-2 could be a risk
factor for low-grade prostate cancer (28).
IGF-I system and life span
Several evidences suggest that insulin/IGF-I signalling
pathways play a pivotal role in the regulation of
R. Baldelli et al.
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longevity (29-32). This hormonal system originated
from a very early common ancestor. In animal models
alterations of insulin/IGF-I signalling increase the life
expectancy. In the nematode Caenorhabditis elegans,
the down-regulation of the insulin/IGF-I pathway
genes (DAF-2, AGE-1 and AKT) extend survival up to
300% (29). The link between reduced insulin/IGF sig-
nalling and longevity was subsequently confirmed in
Drosophila melanogaster (33). The insulin/IGF-1 path-
way became complicated with evolution. Mammals
developed two well characterized hormonal systems:
insulin and GH/IGF-1, with different metabolic and de-
velopmental functions. Rodents with reduced GH
and/or IGF-1 signalling showed extended lifespan as
compared to control siblings. Importantly, these genet-
ic alterations can keep the animals healthy and pro-
tected from several age-related diseases (32, 34, 35).
However, in many of these models the long-lived phe-
notype was exclusively observed for females. In hu-
mans there are several contradictory results on this
topic (31). Bonafe et al. (36) reported that subjects
carrying at least an A allele at IGF-I receptor locus
(polymorphism G/A, codon 1013) have low levels of
circulating IGF-I and are more represented among
long-lived people. A reduced functionality of IGF-I sig-
nalling has been subsequently detected in other pop-
ulations of elderly subjects and centenarians (37, 38).
In addition, several epidemiological studies described
a positive association between serum IGF-I levels and
cancer incidence and mortality (26, 39-41). On the
other hand, in the elderly population relative high cir-
culating IGF-I levels have been associated with a de-
crease in cardiovascular morbidity and mortality (42-
44). Besides, Paolisso et al. (45) reported a decrease
in serum IGF-I and an increase in IGF-I/IGF binding
protein 3 (IGFBP-3) ratio in Italian centenarians com-
pared with aged subjects (70-99 years). This observa-
tion indicates an increase of IGF-I bioavailability in
centenarians. All these contradictory data are proba-
bly related to the complexity of metabolic pathways
and the difficulties of evaluating IGF-I bioactivity in hu-
mans. Another limit observed in previous studies aris-
es from the comparison of serum IGF-I levels between
centenarians and a control group of younger subjects.
This comparison induces a significant bias related to
the age influence of IGF-I. In fact, IGF-I values rise
from birth until puberty then decline with advancing
age. Centenarians’ offspring, meaning people who
have at least one centenarian parent, result to be an
emerging model of longevity without the disadvan-
tages observed in the studies of centenarians. These
subjects are old people (age range 65-85 years) with
a more favourable aging process, when compared
with age-matched controls who do not have long-lived
parents, and with the following characteristics: a low-
er risk for all causes of death; a lower prevalence of
cardiovascular diseases, stroke, diabetes and cancer;
an increased age of onset of age-related diseases
(46, 47). Interestingly, it is possible to compare cente-
narians’ offspring with a demographically-matched con-
trol group (subjects matched for age, sex, ethnicity, par-
ent year of birth, but born from non long-lived parents)
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thus avoiding cohort effects. Suh et al. (38) reported that
female centenarians’ offspring were smaller and dis-
played higher IGF-1 levels, indicative of IGF-1 insensi-
tivity, compared with female controls. In addition, an
overrepresentation of heterozygotes for mutations in the
IGF-1 receptor gene, associated with IGF-1 insensitivity,
was found among Ashkenazi Jewish centenarians.
Therefore, the down regulation of IGF-1 system ob-
served in centenarians and centenarians’ offspring
might significantly extend the lifespan by minimising the
risk of cancer in these subjects, indicating that IGF-1
pathway is an evolutionarily conserved mechanism of
longevity from yeast to humans.
Growth hormone and insulin-like growth factor axis
and sport 
Many relationships between the growth hormone-in-
sulin-like growth factor (GH-IGF) axis [e.g. hormones
(GHRH, Somatostatin, Ghrelin, GH, IGF-1, etc.), GH
and IGF binding proteins (GHBP, IGFBPs), receptors,
proteases, etc.], physical exercise and sport exist. Par-
ticularly, we shortly highlight: a) the main characteristics
of the GH-IGF-1 axis adaptive responses to acute and
chronic exercise-related stress, b) the worldwide use of
GH and IGF-1 as performance enhancing substances
(i.e. as doping) by healthy athletes, and the anti-doping
challenges to detect their abuse, and c) the problem of
sport eligibility/participation and therapy in athletes af-
fected by diseases associated to GH and/or IGF-1 hypo-
or hyper-secretion/function.
GH/IGF-1 responses to physical exercise
Depending on exercise characteristics, acute sub-max-
imal and sprint exercises represent a powerful stimulus
to human GH secretion, and all molecular GH isoforms
increase few minutes after starting a single bout of ex-
ercise (48-50). Whereas few studies exist, chronic ex-
ercise (e.g. training) has been shown to increase GH
pulsatility and/or nocturnal secretion both in healthy
athletes trained above lactate threshold (51) or in
obese subjects affected by metabolic syndrome (52).
GH exerts its specific acute effects directly during and
immediately after exercise, but also IGF-1 seems to
contribute in mediating the GH signals. In fact, conflict-
ing studies have shown an increase, a decrease or no
modifications of serum total or free IGF-1 concentra-
tion after acute or chronic exercise (53). These ob-
served discrepancies are probably related to differ-
ences in experimental protocols and to the numerous
factors influencing the hormones response to exercise
(see after). The mechanisms regulating GH response
to exercise are yet to be fully elucidated. As also re-
ported in excellent reviews (48, 49), different mecha-
nisms have been proposed to explain the origin of the
stimulus for GH response to exercise (e.g. increased
blood lactate or hydrogen ion concentration, oxygen
demand/availability ratio, afferent signals from muscle
metabolic receptors, proprioceptive mechanisms,
adrenergic system, changes in core temperature). At
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hypothalamus-pituitary level, the reported stimuli may
influence GH secretion throughout the combination of
release of GHRH, withdrawal of somatostatin and re-
lease of a GH releasing peptide (GHRP), such as the
putative endogenous GHRP-like ligand Ghrelin. It has
been hypothesized that low intensity exercises may in-
duce moderate GH responses through activation of the
central cholinergic system, resulting in a reduction in
somatostatin release, whereas higher exercise intensi-
ties, once hypothalamic somatostatinergic tone is sup-
pressed, further increase GH release by increasing
GHRH secretion. The role of the inhibition of somato-
statinergic tone in increasing GH secretion after exer-
cise-related stress in humans has been also demon-
strated by evaluating the GH response to exercise fol-
lowing pre-treatments with the somatostatin analogue
octreotide (54) and with pyridostigmine (55, 56). In ad-
dition, the administration of GHRH at the start of an in-
cremental exercise until exhaustion has been shown to
have an additive effect on the GH response to exer-
cise, and the co-administration of GHRH and GHRP-2
at the start of exercise further potentiated GH release
(57), as did the only administration of GHRP-2 before
exercise (58). The characteristics of GH and IGF-1 re-
sponses to physical exercise are related and different-
ly influenced by exercise characteristics (e.g. type, in-
tensity and duration, previous training, number and fre-
quency of exercise bouts, muscles involved, time of
the day), individual factors (e.g. genetic factors, indi-
vidual responsiveness, gender, age, fitness status, nu-
trition), diseases (e.g. GH-deficit, obesity, etc.) and ia-
trogenic factors (e.g. supplements, doping substances,
not prohibited drugs) (49, 59, 60). The biological ef-
fects of GH and IGF-1 during and after exercise are re-
lated to specific modifications of respective peripheral
pathways in different tissues, and to exercise related
modifications of the other substances involved in the
GH-IGF axis physiology (e.g. mainly IGFBP-1 and IGF-
BP-3, etc.) (53, 61). The specific role of GH-IGF axis in
exercise physiology has not been completely evaluat-
ed but many of the GH and IGF-1 related cellular,
metabolic and cardiovascular effects (e.g. increased
cardiac contractility, stroke volume, lipolysis, free fatty
acids availability, uptake and oxidation, fat sensitivity to
catecholamines, protein synthesis, sweat secretion,
cell proliferation, erythropoiesis, etc.) are of great use-
fulness in the physiological body’s adaptation during
and after exercise (i.e. during recovery) (48). Even if
many relationships exist we still have to clarify the ex-
act role of the GH-IGF axis in exercise physiology, par-
ticularly when local GH-IGF pathways in different tis-
sues are concerned, and the possible positive and/or
negative effects of physical exercise-related stress on
such hormonal pathways in different physiological (e.g.
puberty, aging) or pathological conditions (e.g. GH-
deficit, metabolic diseases, osteoporosis).
Doping with GH/IGF-1
GH and IGF-1, and all their respective secretagogues
(e.g. GHRH, Ghrelin), are considered prohibited sub-
stances by the World Anti-Doping Agency (WADA)
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(see at http://www.wada-ama.org/en/World-Anti-Dop-
ing-Program/Sports-and-Anti-Doping-Organizations/In-
ternational-Standards/Prohibited-List/) and by all Na-
tional Anti-Doping Organizations (NADO). GH is one
of the most abused prohibited substances between
athletes and body builders. However, although GH
abuse may increase lean body mass and may im-
prove anaerobic exercise capacity in healthy individ-
uals (62), existing scientific evidences do not support
a possible role of GH in enhancing sport performanc-
es in athletes (63, 64). In our opinion, a great problem
in evaluating the effects of GH/IGF-1 abuse on athlet-
ic performance during official experimental protocols
(i.e. authorized by an ethical committee) is related to
the impossibility to reproduce in healthy athletes the
same type of GH abuse really performed by humans.
In fact, to enhance each specific type of performance
in different sports/physical activities athletes and
body builders usually assume together different ana-
bolic substances (e.g. androgenic anabolic steroids,
GH, insulin), and other prohibited (e.g. central nerv-
ous system stimulants, glucocorticosteroids, etc.) and
not prohibited drugs and supplements (e.g. thyroxine,
PDE5 inhibitors, amino acids, etc.), often at very high
supra-physiological doses and with empirical regi-
mens of administration and associations. Besides the
possible GH/IGF-1 abuse related effects and conse-
quences on performance and health (e.g. antibodies
anti-GH, nausea, headache, hyperglycaemia, dia-
betes, hypertension, fluid retention, arthralgia, gigan-
tism, acromegaly, cancer, etc.) (64), it is of great diffi-
culty to know all the possible effects, adverse events
and health risks related to multi-substances abuses.
In anti-doping, many factors can influence the
GH/IGF-1 abuse detection (e.g. similarity between
endogenous and exogenous hormones, selection of
“reliable markers”, type of assays, normal ranges in
athletes, used biological fluids, anti-doping timing, as-
say’s reliability), consequently, it is still difficult to find
the best and optimal method for detecting doping with
such substances (65, 66). Whereas no definitive tech-
nologies to detect IGF-1 abuse in athletes exist, two
methods are actually used to detect GH abuse: 1) the
isoforms method, that was developed to distinguish
between the proportions of different human GH iso-
forms in physiological conditions (i.e. natural mixture
of 22-KDa and non-22-KDa isoforms) and those
found after recombinant human GH (rhGH: only 22-
KDa isoforms) injection (i.e. increase of 22-KDa and
decrease of non-22-KDa isoforms), 2) the markers
method, that is based on a mathematical calculation
performed by using the serum concentrations of spe-
cific GH-dependent biological markers (e.g. IGF-1,
propeptide of type III pro-collagen) with respect to
control values (65, 66). Even if these two methods
have a reasonable sensitivity and specificity, some
concerns still exist and some new proposed markers
(e.g. c-terminal cross-linked telopeptide of type I col-
lagen, haemoglobin α-chain, etc.) or methods (e.g.
surface plasmon resonance, mass spectrometry, etc.)
to detect GH abuse in athletes should be further eval-
uated (66-68).
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Sport participation in athletes with GH/IGF-1 dis-
eases
Due to the biological effects of GH and IGF-1 in the
mechanisms of response to exercise-related stress
and on body tissues involved in sport adaptation (e.g.
heart, muscles, liver, etc.), sport participation is con-
sidered not physiological and not safe in athletes af-
fected by diseases associated to GH and/or IGF-1
deficit or increase, particularly if other hormones
deficit (e.g. pituitary adenoma) or serious complica-
tions are present. When indicated, athletes affected by
GH/IGF-1 deficit or excess had to start the specific
treatment before starting a competitive sport activity.
According to WADA (see at http://www.wada-ama.org/
en/Science-Medicine/TUE/) and to respective NA-
DO/Federations regulations, in competitive athletes
with GH/IGF-1 deficit it is mandatory to obtain a Ther-
apeutic Use Exemption certificate by the respective
NADO or International Sport Federations before start-
ing GH or IGF-1 treatment at substitutive doses and
after sport participation. In that Countries were sport
eligibility is granted by an external Authority an in deep
and sport-specific pre-participation screening is
mandatory/indicated (i.e. in Italy is mandatory to ob-
tain the sport eligibility certificate by authorized sport
physicians) before starting/re-starting sport participa-
tion in treated athletes with GH/IGF-1 diseases (69).
Due to rhGH pharmacokinetic, in young and adult ath-
letes affected by GH-deficit further studies are war-
ranted to identify the optimal rhGH administration reg-
imen (i.e. morning or evening administration? single or
multiple daily doses?) to guarantee a physiological
competition by reproducing also during and immedi-
ately after each exercise/competition all the effects of
GH on muscles, heart and metabolisms. 
GH-IGF-I axis: drug interferences
In normal cells, insulin-like growth factors (IGF-I and
IGF-II) and their six high-affinity binding proteins (IGF-
BPs) contribute to regulation of cell growth, metabo-
lism, and death. IGFBPs modulate IGF activity by re-
ducing IGF bioavailability to bind to the cell surface
IGF receptors (IGFRs). Balance between growth fac-
tors and IGFBPs is modulated by specific IGFBP pro-
teases. Recent data suggest that IGFBPs may also
exert significant IGF-independent actions. Free, un-
bound IGF-I exerts major actions in carbohydrate,
lipid, and protein metabolism through activation of the
IGF-IRs. This primary receptor for IGF-I is a heterote-
trameric tyrosine kinase membrane receptor. It dis-
plays selective, but not exclusively, binding affinity for
IGF-I, because IGF-IR can bind both IGF-II and insulin
with less affinity ligand. IGF-IR undergoes autophos-
phorylation and conformational changes that trigger
an intracellular signaling cascade through the insulin
receptor substrates 1 to 4 (IRS1- IRS4) and Src ho-
mology and collagen. These molecules activate the
two main downstream signals of IGF-IR: the mitogen-
activated protein kinase and phosphatidylinositol 3-ki-
nase/Akt pathways. IGF-IIR can bind these growth
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factors but acts as a signal decoy and does not trans-
duce the signal intracellularly. The last two members
of the insulin receptor family are the insulin receptor
(IR) and, especially in tumor cells, the hybrid receptors
IGF-IR/IR. The hybrid receptors also signal after bind-
ing IGF-I or IGF-II, similar to the function of IGF-IR. In
normal conditions, both the IGF-IR and insulin recep-
tor (IR) signaling pathways have overlapping functions
and complement each other. Differences in the metab-
olism, availability of the ligand, receptor expression, or
pharmacologic manipulations may change the equilib-
rium in signaling between those two systems. The de-
velopment of cancer is determined by a combination
of environmental factors and genetic predisposition.
Recent evidence suggests that dietary and related
factors such as physical activity and body size may
contribute to malignancy progression through their ef-
fects on the serum concentration of IGF-I and its bind-
ing proteins. The molecular mechanisms by which the
GH-IGF-IGFBP axis is deregulated in malignant cells
is complex, and abnormalities at each of the levels
have been described in different tumors. Overexpres-
sion of the growth factors (IGF-I or IGF-II) or the re-
ceptor, by either gene amplification, overexpression of
convertases or transcription factors, have been ob-
served in different tumors. The polymorphisms in the
genes along the GH1/IGF-1 axis could influence hor-
mone levels and cancer risk, especially breast cancer
(70, 71). Also, post-traslational modifications of the
IGF-IR by glycosylation and the potential co-activation
of the insulin pathway through their co-expression or
through hybrid receptors (IGF-IR/IR) are further poten-
tial mechanisms associated to cancer. Modification of
the concentration of IGF-BPs (especially IGFBP-1,
IGFBP-3, and IGFBP-5) or of the insulin receptor can
modify the overall activation of the pathway. Finally,
lost of IGF-IIR, a negative regulator of IGF signaling
that works by as a decoy by binding the growth factor,
could drive cells into an IGF-IR - dependent growth.
Expression of the IGF-IR has been reported in a broad
panel of tumor types. Being so ubiquitous, IGF-IR
could play different roles in different tumor types or
cellular contexts. Some tumors may be dependent on
IGF-IR signaling for survival, and its inhibition might
trigger apoptosis and a subsequent cytotoxic effect.
This could probably be the mechanism behind the dra-
matic responses observed in tumors like Ewing sarco-
mas. Some other tumors may rely on IGF-IR for prolif-
eration, like neuroendocrine tumors. Inhibiting IGF-R
will produce a cell cycle arrest and, thus, a cytostatic
effect. Other tumors may have IGF-IR overexpression
as a survival mechanism against cytotoxic insults, and
combining chemotherapy with an IGF-IR inhibitor may
overcome this mechanism of resistance. This could be
the case of the observed synergy between chemother-
apy or radiotherapy and IGF-IR inhibition, as well as
with other targeted therapies like trastuzumab, EGFR
inhibitors, and hormone therapies. Recently, discover-
ies of GH-IGF-IGFBP axis’s actions in cancer allowed
the design of specific inhibitors that may interrupt the
signaling associated with this axis. The ability to ma-
nipulate these pathways hold not only significant ther-
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apeutic implications but also increase the chance of
deeper insight about the role of the axis in carcinogene-
sis and metastasis. About 25 molecules are currently at
different stages of development, including both tyrosine
kinase inhibitors and monoclonal antibodies (72, 73).
Further approaches are being developed, including pep-
tides, proteins, or antisense oligonucleotides that antag-
onize IGF-IR. However, these agents have not reached
the clinic. Because of compensatory crosstalk between
IGF-1R and IR, dual IGF-1R and IR tyrosine kinase in-
hibitors may have superior anti-tumor activity compared
to anti-IGF-1R specific antibodies (74). Hyperglycemia,
mild skin toxicities (rash, flushing, pruritus, acne), and
fatigue as common toxicities of these drugs. Other ob-
served toxicities, like reduction in CD4+ lymphocytes,
thrombocytopenia, and transaminitis, do not seem to be
related with the mechanism of action but with specific
antibodies. Hyperglycemia seems to be frequent
(around 20%) but tolerable, mild to moderate (grades 1
and 2), reversible, and manageable with an oral hypo-
glycemic drug, such as sulfonylureas. Although still pre-
mature, these promising data, consistent with the effect
seen with chemotherapy, justify its investigation in can-
cer types like prostate cancer, advanced head and neck
cancer, and locally advanced pancreatic cancer where
radiation therapy forms part of the main initial treatment.
The estrogen pathway and its relation with IGF has been
explored in tamoxifen-resistant breast cancer models.
This resistance is in part mediated by IGF-IR/mitogen-
activated protein (MAP) kinase signaling pathway and c-
Src seems to be one of the critical elements. Thus, the
small molecule XL-228, tyrosine kinase inhibitor of both
Src and IGF-TK seems a good candidate for develop-
ment in this setting. Clinical experiments demonstrated
no significant modifications in GH response to GHRH af-
ter acute or chronic treatment with tamoxifen compared
with the basal test. On the contrary, chronic tamoxifen
treatment induced a significant decrease in serum IGF-I
levels. These data confirmed the inhibitory effect of ta-
moxifen on IGF-I production, but seem to exclude the
possibility that this effect may be due to an inhibition of
GH secretion (75). Results of translational research
aimed to identify biomarkers associated with sensitivity
to IGF-1R/IR inhibitors remains the only way to select
the right patients who would benefit of the appropriate
single-agent therapy, or the most suitable combination
therapy. Mutations in downstream signaling pathways
such as PIK3CA, the expression of IGF axis ligand-re-
ceptor pairs, markers associated with epithelial-mes-
enchimal transition, free IGF1 ligand levels, and a host
of multi-gene biomarkers are the most promising molec-
ular features that may predict sensitivity to IGF-1R/IR in-
hibitors.
GH/IGF-1 axis and oncological risk
Many experimental in vitro models evidenciated the link
between GH and IGF system with cancerogenesis
processes. In 1950 (76) it was reported that high-dose
treatment with extracted GH was able to induce devel-
opment of lungs, adrenals, ovaries, and breast neopla-
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sia in female rats. Studies with transgenic mice con-
firmed the role of GH in animal oncogenesis (77); GH
was found to stimulate the cellular proliferation of differ-
ent cancer cell lines, including human leukemic lympho-
cytes and murine erythroleukemic cells. Another impor-
tant aspect confirming the effect of GH on carcinogene-
sis is the GH synthesis in a different number of extrapi-
tuitary organs including both normal and neoplastic
mammary tissues so a possible local paracrine/au-
tocrine effects independent of or additional to endocrine-
mediated IGF-I action could be supposed (78). Further-
more in prostate cancer cell lines, GH is able to increase
cell proliferation probably due to the coexpression of pi-
tuitary GH as well as GH-R mRNA isoforms; so an au-
tocrine-paracrine pathway seems to be able to stimulate
prostate growth (79, 80). Unlike GH, the IGF system
modulates the oncogenesis process at different steps
(81); once quiescent cells are made competent and the
stimulation with IGF-I is sufficient to complete the cell
cycle, promote cell proliferation and arrest apoptosis,
both in normal and cancer cell lines (82, 83). The effects
of IGF-I stimulation is related to the density and function-
ality of the IGF-IR and this is fundamental for the IGF-I-
mediated proliferation (82). A confirmation of IGF-I/IGF-
IR involvement in oncogenesis has been shown in vitro
experiments where knockout of IGF-IR gene was capa-
ble of decreasing cell proliferation and increasing apop-
tosis. Moreover the IGF-I/IGF-IR system seems to fur-
ther influence tumoral progression promoting different
mechanisms such as adhesion and migration of cells,
angiogenesis within neoplastic tissues and surrounding
areas (82, 84). 
In vitro, IGF-I does not seem to promote cellular trans-
formation, rather seems to stimulate proliferation of
transformed cell clones and the growth of pre existing
tumor tissues. In fact liver-specific IGF-I-deficient mice
treated with chronic IGF-I administration are character-
ized by the presence of processes of growth and
metastatic proliferation of colon adenocarcinomas trans-
planted cells (85). As for GH, also for IGF-1, endocrine
and autocrine/paracrine effects in a number of tissues
and cell systems are reported. Regulation of cancer
growth through an IGF-I/IGF-IR-mediated autocrine/
paracrine loop has been reported by the demonstration
of IGF-IR mRNA expression in colon carcinoma, more
abundant than IGF-I mRNA expression (86), and pre-
dominates in samples from colon tumor vs the adjacent
normal mucosa, a condition suggestive of paracrine/au-
tocrine modulation (87). In situ hybridization studies
have evidenciated that IGF-I is expressed in the stromal
cells and very rarely in the epithelium of breast cancer
while IGF-IR has been found on neoplastic breast ep-
ithelial cells suggesting the presence of a paracrine in-
teraction (88). IGF-I levels are significantly higher in
women with breast cancer (89) and in men with prostate
tumors (90), respect to normal population. In the Euro-
pean Prospective Investigation into Cancer and Nutrition
(EPIC) study, high circulating IGF-1 concentration was
positively associated with risk for prostate cancer (25).
In a study of survey on 152 cases of prostate cancers,
among nearly 15,000 men subjected, Chan et al. (91)
provided evidence of a 2.4-fold greater cancer risk asso-
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ciated with IGF-I levels in the upper quartile of the nor-
mal range, compared with patients whose IGF-I values
were in the lower quartile. Another study conducted by
Hankinson et al. (92) reported that the relative risk of
breast cancer in premenopausal women with IGF-I lev-
els in the upper tertile of the normal range was 2.3 times
higher than in patients with IGF-I in the lower tertile. In
particular women below age 50 yr, the highest IGF-I ter-
tile was associated with an increase in breast cancer
risk to 4.6 and, after inclusion of IGFBP-3 levels in the
multivariate analysis, to 7.3 (92). Ma et al. (93) analyzed
IGF-I and IGFBP-3 levels in 193 men diagnosed with
colorectal cancer over a 12-yr follow-up, and reported
that the relative risk in men having IGF-I levels in the top
quintile was 2.5 times greater than in those whose IGF-
I was at the bottom quintile. Inversely, the relative risk
calculated by IGFBP-3 quintiles was 0.28 for top vs bot-
tom quintile. Another important aspect suggesting the
link between the GH/IGF system and human cancers is
the demonstration that GHRH-antagonists, GH-antago-
nist, and somatostatin analogs elicit antineoplastic activ-
ity by altering the GH/IGF-I axis at the pituitary level or
by inhibiting autocrine/paracrine activity of GHRH, GH,
and IGFs (94-97). Moreover, preliminary findings have
indicated that the GH-antagonist decreased proliferation,
stimulated apoptosis, and reduced metastatic spreading
of MCF-7 breast cancer cells (78). 
GH/IGF-I axis and heart
GH and IGF-I are potent cardiotrophic factors and their
involvement is similarly crucial in cardiac diseases. Their
role will be here examined relatively to three main set-
tings: the process of cardiac regeneration, the chronic
consequences of altered GH secretion and cardiovascu-
lar data from the general population. Analysis of these
topics will then try to provide reasonable argumentations
for their therapeutic use in heart disorders. 
Cardiac regeneration mediated by GH/IGF-I
Apoptotic death and necrosis are relevant events in a
number of cardiac diseases. Experimental cardiac in-
farction is associated with an upregulated autocrine
IGF-I system which is capable of stimulating DNA
replication and mitotic division in viable cardiac my-
ocytes, as confirmed by enhanced proliferating cell
nuclear antigen (PCNA) message and transcript (98).
IGF-I directly promotes survival and proliferation of
resident cardiac stem cells, with consequent improved
myocardial regeneration after myocardial infarction
(99). This antiapoptotic effect also comprises of indi-
rect actions, as mesenchymal stem cells overexpress-
ing IGF-1 can attenuate infarct by stimulating VEGF
expression, which then modulates neovascularization
and myogenesis (100). In humans, rhGH increases
IGF-I levels in parallel with circulating endothelial pro-
genitor cells (EPC, a sensible predictor of cardiovas-
cular outcomes), these latter exhibiting improved
colony forming and migratory capacity, enhanced in-
corporation into tube-like structures and augmented
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eNOS expression (101). IGF-I treatment of human
EPCs improved function and attenuated cellular
senescence, further suggesting a role for IGF-1 in ag-
ing EPC. Based on the previous, local IGF-I delivery
and genetic manipulation of IGF-I expression seem ef-
fective tools to obtain a modulation of cardiac regen-
eration. These forms of treatment could be repeated
over time to reduce progressively tissue scarring and
expand the working myocardium.
Cardiovascular consequences of GH and IGF-I ex-
cess
Cardiomegaly is a hallmark of visceromegaly associ-
ated with acromegaly. It is traditionally thought to
progress toward cardiac failure unless GH-excess is
removed. Interindividual differences in cardiac in-
volvement likely depend on varying age, familiarity,
duration of disease, resistant arterial hypertension (up
to 50% of patients are hypertensive), longstanding di-
abetes mellitus (about 1/3 patients are glucose-intol-
erant and just as many are diabetic), ventilatory disor-
ders (obstructive sleep apnea affects ~80% of cases),
arrhythmia (present in up to 30-40% of patients, being
mainly supraventricular and largely conditioned by
cardiac hypertrophy and sleep apnea), as well as car-
diac valve disease (mitral and aortic regurgitation af-
fects 75% of patients, mostly those with cardiac hy-
pertrophy). The interplay of altered glucose home-
ostasis, hypertension and aging explain a stepwise in-
crease in the prevalence of cardiac hypertrophy, dias-
tolic and systolic dysfunction (102). Two main goals
should be, intuitively, pursued to modify long-term car-
diovascular consequences of acromegaly. First, it is
crucial to achieve complete control of GH hypersecre-
tion by neurosurgical cure or pharmacological man-
agement. Somatostatin analogs are a valid tool to
achieve control of cardiovascular complications of
acromegaly and recent studies displayed similar glob-
al effects of octreotide LAR and lanreotide autogel on
left ventricle mass, diastolic and systolic function. The
GH-antagonist pegvisomant has also been found to
yield significant cardioprotective results in a 18-month
analysis (103). Treatment with pegvisomant reduces
heart rate and improves rhythm abnormalities in
acromegaly (104). Secondly, effective complementary
treatment of comorbidities is essential: antihyperten-
sive agents, hypolipemic and antidiabetic compounds,
as well as noninvasive mechanical ventilation are all
instrumental to achieve full control of cardiopulmonary
complications of acromegaly. In this scenario, litera-
ture data linking heart valve disease to the use of
dopamine-agonist warrant appropriate surveillance in
acromegalic patients treated with high-dose cabergo-
line.
Cardiovascular effects of GH deficiency (GHD)
It is known that hypopituitary patients with GHD bear
an increased risk for coronary artery disease and im-
paired cardiac function leading to a 2-fold greater car-
diovascular mortality than the general population.
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Childhood- and adulthood-onset GHD reduces left
ventricle mass and diameter proportionately to the du-
ration of GHD or to IGF-I levels. This is concomitant to
an impairment of cardiac performance at peak exer-
cise and abnormal diastolic filling (105). In large co-
horts, cardiac dysfunction occurs proportionately to
the severity of GHD, with systolic and diastolic abnor-
malities affecting 45-78% of GHD patients (106). The
so-called hypokinetic syndrome of GHD coexists with
other key risk factors, which include visceral adiposity,
insulin resistance, atherosclerosis and hypercoagula-
bility. Importantly, patients with GHD following cure of
acromegaly or Cushing’s disease are more prone to
develop hypertension, diabetes mellitus and stroke
than those with GHD from any other cause (107). The
influence of obesity is equally important as seen in
studies on adults with Prader-Willi Syndrome, a mono-
genic disorder associated with morbid obesity and
GHD (108). In populations with classical GHD, GH
therapy produces positive cardiac effects depending
on patient’s medical history, multiplicity of pituitary de-
ficiencies and comorbidities. A metanalysis reported
that GH treatment was associated with a significant in-
crease in LV mass (+10.8 g), septum thickness (+0.28
mm), LV posterior wall (0.98 mm), end-diastole diam-
eter (+1.34 mm), and stroke volume (+10.3 mL), while
overall effect sizes were not significant for most in-
dices of diastole (109). 
General population studies
Most studies have been so far published on IGF-I, with
a role for GH necessitating further evidences. IGF-I is
thought to influence cardiovascular disease (CVD)
through complex mechanisms, yet results are con-
trasting. Following a Danish study on ischemic heart
disease (IHD) that reported a significant association
between the 15-yr risk and low IGF-I and high IGFBP-
3 levels (44), the Rancho Bernardo Study confirmed
the inverse association between IGF-I levels and IHD
mortality in subjects aged over 50 yrs but no associa-
tion with non-IHD cardiovascular (CVD) mortality
(110). A key study by Lamberts’ group found IGF-I
bioactivity assessed by kinase receptor activation (but
not total or free IGF-I levels) to be associated with ex-
tended survival and reduced CVD risk in elderly men
followed up for > 8 yrs (111). At variance with these
data, the NHANES and the Third NHANES Mortality
Study carried out in 6226 adults aged 20 yr or older
failed to confirm these associations (112). Moreover,
there is evidence that a reduced GH-IGF1 signaling
increases lifespan in animal models, while a blunted
activity in the IGF-I pathway also seems to be associ-
ated with longevity in humans (38). In line with this, a
population-based study of 642 individuals aged 50-89
yrs found that IGF-I levels in the fourth quartile were
independently associated with > 5-fold increased risk
of cardiac heart failure (113). The association between
IGF-I and mortality is, therefore, not linear and diver-
gences may result from unadjusted confounding phe-
nomena, assay drawbacks or differences in demo-
graphic data. These discrepancies are partly recon-
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ciled by recent evidence showing that both elevated
and reduced IGF-I levels may double the risk of CVD
mortality, thus that a U-shaped relationship links IGF-
I to CVD mortality (114).
Cardiovascular effects of GH or IGF-I 
administration
In the last 15 years, debated evidence has accumulat-
ed on GH or IGF-I utility as therapeutic agents in car-
diac failure. Chronic heart failure (CHF) is featured by
(primary or secondary) structural and functional car-
diac abnormalities that coexist with altered vascular
reactivity, this latter being primarily due to endotheli-
um-dependent defects and loss of bioactive endothe-
lial nitric oxide. Increased peripheral vascular resist-
ance further aggravates LV failure. Importantly, GH
improves eNOS activity and increases NO availability
via IGF-I. Following the description of a GHD patient
improving dilated cardiomyopathy with rh-GH treat-
ment (115), several subsequent studies have suggest-
ed that rhGH may increase LVEF and decrease sys-
temic vascular resistance in CHF patients. These ef-
fects show a rapid onset and depend not exclusively
on the improved endothelium-dependent vasodilata-
tion, but also on modifications in loading conditions,
myocardial contractility and cardiac morphology. A
meta-analysis showed significant overall effects of
rhGH on LV walls, end-diastole volume, ejection frac-
tion, systemic vascular resistance, NYHA class, exer-
cise duration and VO2 max in CHF patients (116). Op-
positely, double-blind placebo-controlled studies on
rhGH effects failed to show direct effects on cardiac
function or structure in CHF patients of different aeti-
ologies (117). Therefore the results are conflicting
(118). Scant but relevant are the findings on the ther-
apeutic usefulness of IGF-I. Acute infusion of rhIGF-I
in healthy subjects increases cardiac output, heart rate
and stroke volume significantly (119). The possibility
that IGF-I may be beneficial in cardiac disorders has
been explored in CHF patients, and rh-IGF-I yields
positive effects on the cardiac index, stroke volume
and peripheral resistance (120). However, long-term
effects are unknown. It is also interesting to note that,
recently, similar results on LVEF, LVM, and exercise
capacity were reported after treatment with GH releas-
ing hormone and ghrelin in patients with CHF (121). 
GH/IGF-I axis and glucose metabolism
It is well known that diabetes and insulin resistance
are the major determinant of metabolic syndrome in-
volving in cardiovascular mortality (122, 123) and that
alterations of the GH/IGF-I contribute in determining
cardiovascular disease with increased risk for cardio-
vascular morbidity and mortality both in GH deficiency
(GHD) and excess (103). The GHD mediated effects
on the cardiovascular function are directly played on
the heart and endothelium but also in indirectly man-
ner by increasing all cardiovascular risk factors with
particular role made by central adiposity, insulin resist-
ance and finally by glycemic metabolic derangement
and metabolic syndrome (124). Visceral obesity is a
central feature of metabolic syndrome and further-
more is well known that obese subjects have a func-
tional GH deficiency; in a recent paper Di Somma
showed an higher prevalence of metabolic syndrome
in GHD obese patient than GH sufficient obese patient
suggesting a possible maladaptive role for functional
GHD in obesity with increased metabolic risk factors in
severe obesity independently from BMI per se (125).
Epidemiological perspectives studies confirm the as-
sociation between low IGF levels and all causes and
cardiovascular disease mortality (110) and in prospec-
tive observational study IGF-I showed a significant in-
verse association with subsequent 2-h glucose con-
centrations independently correlates of IGF-I and risk
factors for glucose tolerance providing protective role
for IGF-I against development of glucose intolerance
(126). Furthermore in large epidemiological cohort
study type 2 diabetes showed a curvilinear association
with IGFI SDS (127) and in recent cross sectional epi-
demiological study IGFI is an independent predictor of
diabetes (128). Many studies have confirmed that GH
therapy in GHD patients reduce visceral fat, improves
insulin sensitivity and atherosclerotic profile with in
turn reduction in prevalence of cardiovascular risk fac-
tor and metabolic syndrome (129). High prevalence of
metabolic syndrome in adult GHD patients (respec-
tively 51.8% in USA and 28.6% in Europe) was recent-
ly reported in a large series without prevalence differ-
ence after GH replacement although baseline MetS
status and obesity were strong predictors of Mets af-
ter GH treatment (130). Taking metabolic advantage
from molecular analogy between insulin and IGFI
some study demonstrated either an increase in insulin
sensitivity and glycemic tolerance in type 2 diabetes
with sever insulin resistance (131) or a reduction in in-
sulin doses in type 1 diabetes using IGFI administra-
tion or equimolar IGFI-IGFBP3 complex (132, 133). In
acromegalic patient a reduced life expectancy was re-
ported reduced first due to cardiovascular disease
(134) with hypertension and glucose intolerance as
important independent contributory factors to the vas-
cular morbidity associated with acromegaly (135).
Retrospective comparative study reported a signifi-
cant increase of cardiovascular risk factors in acrome-
galic patients matched for age and gender from gen-
eral population with a prevalence of diabetes even 2.9
fold higher (136) while diabetes’s prevalence in
acromegaly ranges in different study from 19-56%
(106). Although somatostatin and somatostatin ana-
logues reduce insulin secretion a recent metaanalysis
on somatostatin analogues on glucose homeostasis
suggest that modifications of glucose homeostasis in-
duce by SSA may have an overall minor clinical im-
pact (137). Non detrimental SSA therapy’s effect on
glucose metabolism was confirmed in long term first
line SSA therapy without any differences between
SSA treated and surgically cured patients with in-
creasing BMI as major predictor of deterioration of glu-
cose tolerance (138). In patients with acromegaly re-
ceiving lanreotide as primary treatment only 17% had
R. Baldelli et al.
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a worsening of glucose status (60% had no change,
27% had an improvement) and deterioration was sig-
nificantly associated with smaller GH decreases dur-
ing primary lanreotide treatment (139). Only limited
data on glucose metabolism during pasireotide (SOM
230) a new multireceptor ligand SSA analogue in
acromegaly are now available with significative in-
crease in HbA1c levels after 3 months’s therapy (140)
according with octreotide and lanreotide 6 and 12
months therapy ’s studies (141). Data from pegviso-
mant (a new GH receptor antagonist) therapy in
acromegaly demonstrate a significant reduction on
Hba1c levels in diabetic and non diabetic patients with
a correlation with IGFI reduction. Urbani C et al. found
that the prevalence of diabetes or impaired glucose
tolerance is higher during SSA than at diagnosis or
during pegvisomant (142). Increase in insulin sensitiv-
ity after short term therapy (143) by a reduction in
overnight endogenous glucose production related to
related to reduced FFA levels was also demonstrated
(144) according with data after acute pegvisomant ad-
ministration using hyperinsulinemic euglycemic clamp
in healthy subjects (145). Conflicting data from d3GH
receptor polymorphism (a common polymorphic GH
receptor variant) impact on metabolic phenotype are
emerging in GH deficiency and acromegalic patients.
In fact in GHD adults patients the presence of d3GH
receptor polymorphism may cause a major sensitivity
to negative metabolic GH effect (146). In acromegalic
patients was reported a slightly higher prevalence in
diabetes mellitus in d3GHR acromegalic patient (147);
but on the contrary Montefusco reported a decreased
BMI with a preponderance of normal glucose toler-
ance between d3GHR patients in contrast to fl/flGHR
but similar prevalence of overt diabetes mellitus (148).
Insulin resistance, impaired glucose tolerance and di-
abetes mellitus due to acromegaly disease generally
improve with the GH/IGFI normalization but no com-
parative study are available on diabetes’s best thera-
py and we have just suggestions pointed to oral sec-
retagogue hypoglicemic agents and or insulin therapy,
particularly new long acting insulin analogues when
metabolic disease arise during SSA analogues thera-
py in responsive patients (149, 150) or Pegvisomant’s
use in somatostatin analogues resistant patients with
coexistent diabetes mellitus (151).
GH/IGF-1 axis and reproduction
Growth hormone (GH) is obligatory for growth and de-
velopment, but it has also an important role in the re-
productive process. It is required for sexual differenti-
ation and pubertal maturation and it participates in go-
nadal steroidogenesis, gametogenesis and ovulation
(152-154). The effects of GH are exerted at three lev-
els: a permissive action on gonadotropins secretion
and action, a peripheral direct, or IGF-1 mediated, ef-
fect on gonadal development, and a paracrine effect,
by locally produced IGF-1 (155). Lobie et al. used im-
munohistochemistry to localize GH receptor and bind-
ing protein and found intense immunoreactivity in the
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male reproductive system, including Leydig and Ser-
toli cells, vas deferens, prostate, ductus epididymis
and seminal vesicles (156). This finding suggested
that GH might stimulate local IGF-1 production. This
parallel what is seen in ovarian tissues, where sever-
al authors found a strongly GH-binding activity, GH re-
ceptor (GH-R) immunoreactivity and mRNA encoding
GH-R (157). The need for local GH and IGF-1 produc-
tion has been related to the presence of a haemato-
gonadal barrier: even if the gonads are highly vascu-
larized, some cells in the ovary and testis must remain
physically separated from systemic circulation since
might be antigenic. For this reason some GH actions
might mediated by hormones locally produced. In-
deed, the entire GH /placental lactogen (GH/PL) gene
cluster (chromosome 17), comprising five highly relat-
ed genes (GH-N, PL-L, PL-A, GH-V and PL-B), is tran-
scribed in the human testes and ovary, with GH-V (the
GH variant) being the most active gene transcription-
ally (158, 159). In summary, GH presents a large vari-
ety of biological actions on reproductive tissues and
IGF-1 may mediate some, but not all, of these effects.
Nevertheless, the clinical role of systemic and
paracrine GH/IGF-1 axeses have seldom been ex-
plored. Early studies documented that GH is required
for normal sexual maturation in mammals: Laron and
others showed an association between isolated GH
deficiency in boys and delayed puberty, with the fre-
quent clinical observation of micropene (160, 161) or
smaller testes. Later on, Laron also showed that in
these patients the administration of GH restored nor-
mal pubertal development (162). GH has been also
implicated in the development and function of wolffian
duct-derived structures such as the prostate and sem-
inal vesicles (163). Regarding female reproduction, it
was suggested a role of GH as intraovarian modulator
and, in a series of in vitro studies, it was found that in-
cubation of granulosa cells with insulin and IGF-1 in-
creased their responses to stimulation by FSH (164,
165). So the co-treatment with GH augmented the
ovarian response to stimulation by gonadotrophins.
Furthermore, some studies found that GH may stimu-
late particular follicle populations selectively and pro-
liferation of luteinized granulosa cells via an FSH and
IGF-1-independent mechanism (166-168). On the ba-
sis of these encouraging results and after demonstra-
tion in pubertal boys of a clear effect of GH on Leydig
cell function and on pubertal maturation of the testis, it
was suggested an additional role of GH in spermato-
genesis. These studies were mainly performed in the
80s’ and 90s’, on very small cohort of men, in uncon-
trolled studies. Nevertheless some of the findings are
of interest showing a link between GH deficiency and
some alterations of spermatogenesis. Shimonovitz et
al. found more than 50% of azoospermic men, as
compared to 18% of oligozoospermic men, showed
subnormal GH response, as determined by the cloni-
dine test. They proposed that GH may be involved in
maturation arrests (169). GH effectively increases
sperm concentration and/or motility in males resistant
to other forms of fertility treatment in some, but not all,
clinical studies with infertile patients (170-172). It has
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been proposed that GH affects sperm motility directly,
or by actions mediated through Sertoli cells independ-
ently of IGF-1 (155). GH actions on spermatogenesis
also can be mediated by influences on testosterone
synthesis: GH therapy in GH-deficient males aug-
ments the testosterone response to human chorionic
gonadotropin, increases plasma estradiol levels, and
increases the abundance of gonadotropic binding
sites (171). The putative steroidogenic action of GH
could involve hepatic/local IGF-1 modulation, although
in vitro studies suggest an IGF-1-independent role for
GH in Leydig cell function: Kanzaki and Morris have
shown that GH increases androgen synthesis in rat
progenitor Leydig cells. GH is thought to exert its ef-
fect at initial ratelimiting steps in the steroidogenic
synthetic pathway, acting on synthesis of StAR protein
(which regulates the translocation of cholesterol to the
inner mitochondrial membrane) and 3β-hydroxys-
teroid dehydrogenase (3βHSD) (which converts preg-
nenolone into progesterone) (173). Also reproductive
dysfunctions in some women have been associated
with partial GH deficiencies. Clinical studies have
shown that GH therapy may be useful in some, but
not all, infertile women (174, 175). GH administration
to hypogonadotrophic anovulatory women significant-
ly reduces the dosage and duration of hMG treatment
required for ovulation induction and increases the
percentage of successfully treated patients (175). GH
therapy may also improve the success of in vitro fer-
tilization techniques by enhancing the hyperovulatory
response to hMG (176). Although the optimal thera-
peutic role of GH in induction or ovulation and sper-
matogenesis has yet to be totally defined, the reality
of its interaction with gonadotrophins has clearly been
demonstrated in vivo (177). More recently, the avail-
ability of human recombinant GH, better definition of
GH deficiency, allow a rigorous exploration the poten-
tial clinical use the strong connection between physi-
ology of reproduction and growth and development.
In addition, systemic and local GH seems to have a
complementary autocrine or paracrine actions reflect-
ing a ‘fine-tuning’ mechanism to regulate gonadal
function (178).
GH/ IGF-I and bone
Growth hormone (GH) and its mediator insulin-like
growth factor I (IGF I) plays an important role in longi-
tudinal bone growth and in acquisition of peak bone
mass (PBM) during childhood and adolescence. Stud-
ies human and animal models have highlighted the in-
tegral effects of GH and IGF-I on skeletal develop-
ment, linear growth, and the achievement of peak
bone mineral density. The acquisition of peak bone
mass, occurring at the end of skeletal maturation, is
an important determinant of later development of os-
teoporosis and subsequent fracture risk (179). In addi-
tion, to the effects on longitudinal growth after the clo-
sure of epiphyseal growth plates, GH and IGF-I are
anabolic hormones and have a key role in the regula-
tion of bone modelling and remodelling (180). GH acts
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both inducing IGF-I in bone or playing direct effects on
skeletal cells (Giustina A et al. 2008). The effects of
GH and IGF on skeleton are modulated by interactions
between circulating IGF-I and IGFBPs and the locally
produced IGF-I and IGFBPs. In addition, the skeletal
actions of GH/IGF-I axis are regulated by systemic
hormones, such as sexual hormones and PTH (180).
In particular, IGF-I and PTH have synergistic actions
on bone and some effects of the anabolic actions of
PTH are mediated by local production of IGF-I, as has
been shown in vitro and in vivo studies both in animals
and humans. On the other hand, PTH can induce
skeletal IGF-I expression both in vitro and in vivo
(181). Based on the aforementioned findings, it could
be argued that diseases affecting GH/IGF-I axis in-
duce skeletal abnormalities. In this section we will dis-
cuss skeletal abnormalities occurring in GHD and
acromegaly, and the role of GH and IGF-I in the osteo-
porosis.
GH deficiency and Bone
GHD syndrome is mainly characterized by high fat
mass with central adiposity and low lean body mass,
dyslipidemia, hypertension, elevated inflammatory
markers, insulin resistance, increased intima-media
thickness, reduced exercise capacity, impaired quality
of life (QoL), low bone mineral density (BMD) and in-
creased risk of fractures (182). As proof of the state of
low bone turnover, serum levels of osteocalcin and
bone resorption markers are decreased and the same
patients report a renal, skeletal, and intestinal cell in-
sensitivity to PTH, leading to a mild state of PTH re-
sistance and increased serum PTH levels (180). In the
development of osteopenia a main role is played by
GHD as suggested by the reduction of bone mineral
density (BMD) both in patient with isolated GHD that
in patient with multiple pituitary hormone deficiencies
(MPDH) (183). In addition, only patients with very se-
vere or severe GHD have a significant reduction of
BMD, associated with abnormalities of bone markers
(183). This confirms the importance of GHD in patho-
genesis of osteopenia in hypopituitaric patients (183).
Associated other pituitary hormone deficits and/or re-
placement therapies have also been proved to be im-
portant factors in the pathogenesis of bone loss (180)
as well as the age of onset of GHD and the age of the
patients (180). Infact, in patients with childhood-onset
GHD there is a marked reduction in vertebral BMD (T-
scores often between 1 and 2; about one third of the
patients have T-scores of 2.5 or less) (180). Other
way, the vertebral T score results normal (1 or above)
in patients with adult-onset GHD (180). The reduced
bone mineral content and density in patients with
childhood-onset GHD is probably due to the lack of at-
tainment of bone mass during adolescence and the
longer disease duration while the pathogenesis in pa-
tients with adult-onset GHD it is less clear (180, 183).
The correction for height has demonstrated that short
stature is less significant in the determination of a low-
er BMD observed in childhood-onset GHD, whereas
changes in body composition may play a significant
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role (180). There is no definitive data demonstrating
an increase in the risk of fractures in patient with de-
creased bone mass for untreated GHD. However, the
risk of non-vertebral fractures (prevalently localized at
the radius) has been found to be about 3 times more
often in untreated GHD patients, suggesting a loss of
cortical bone (180). As far as vertebral fractures, re-
cent studies reported an increased incidence of verte-
bral deformities (180). Other pituitary hormone defi-
ciencies or hormonal replacement therapy do not influ-
ence the prevalence of bone fractures while the de-
gree of GHD affects this prevalence (180). In particu-
lar, in GHD patients, BMD does not correlate with the
prevalence of fractures (180) as well as in other forms
of secondary osteoporosis (180). On the other hand,
these patients had an increased risk of falls for de-
creased muscular strength and impaired vision could
be contributed to risk of fracture (180). For what con-
cerns the GH replacement therapy it has been ob-
served an initial reduction in BMD due to a stimulation
of bone turnover by GH that leads to an increase in re-
modeling space (182). However long-term GH re-
placement is associated with an increase of bone
mass (182). Jørgensen et al. found an increase of
bone markers during the study and an increase in
bone mineral content (BMC), BMD and bone mineral
area (BMA) in the lumbar spine (L2-L4) and total body
measurements after nine months of GH replacement
therapy and in the femur (not BMA) measurements af-
ter a longer therapy. These different effects in the lum-
bar spine, total body and femur can be explained
probably with the different actions of GH on cortical
and trabecular bone. GH replacement therapy in-
creases lumbar (L2-L4) spine and femur neck BMD in
younger as well as elderly GHD patients (184). Effects
of GHD on bone metabolism and the results after GH
replacement therapy are influenced by the sex of pa-
tients, too. Many authors have put in evidence that af-
ter 18-24 months of GH therapy there was a small in-
crease of BMD in male patients with adult- onset
GHD, instead there were not significant evidences of
increase in female patient. In a recent study, a 2 yr GH
replacement normalizes IGF-I levels, increases bone
mass and improves bone turnover both in men and in
women with GHD without any difference between the
two groups, provided that the dose of GH was modu-
lated on the basis of IGF-I levels. Women receiving
oral estrogens should receive a GH dose approxi-
mately doubled, as compared to men and women not
receiving oral estrogens, to achieve similar effects on
bone density and turnover. In particular, GH replace-
ment dose to be successful on bone mass and
turnover depend on gender in hypopituitary patients
aged below 50 yrs (185). 
GH excess and Bone
Gigantism and acromegaly are conditions associated
with elevated levels of GH and IGF-I. In these patients
the body water and the lean body mass are increased
and the body adiposity is decreased (179). As concern
the bone metabolism, these patients have an increase
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of bone turnover, calcium kinetics and bone histomor-
phometry (180). Both bone formation and resorption
are increased, but the increase of bone resorption
markers is higher than the bone formation markers.
These difference could be associated to the degree of
bone loss observed. Moreover there is a correlation
between serum GH and IGF-I levels with bone mark-
ers (180). In addition, active acromegaly is associated
with increased serum concentrations of PTH, 1,25-di-
hydroxyvitamin D3, calcium, and phosphorus (180),
probably due to the GH stimulation on parathyroid
gland (180). The cortical and the trabecular bone have
a different sensitivity to GH excess so the skeletal site
play an impotant role in the determination of the ef-
fects of GH excess on BMD (180). In fact acromegal-
ic patients have an increased in BMD at the lumbar
spine which is rich in trabecular bone, whereas there
is an increase in the BMD at the forearm where the
cortical bone has a major representation (180). In
spite of the variability of data on BMD in acromegaly,
due to the different densitometry techniques, the re-
sults obtained with peripheral quantitative computer-
ized tomography and bone biopsies have demonstrat-
ed different effect of the GH/IGF-I effects on the tra-
becular and cortical bone (180). In acromegaly other
factors could influence bone BMD such as age, gen-
der, and the presence or absence of hypogonadism
(180). In fact, it has been observed that the decrease
of vertebral BMD is correlated with the increase of the
duration of the hypogonadism (180). Even if there is
not a large number of studies about the risk of frac-
tures in acromegaly (180) postmenopausal women
with active acromegaly have a higher incidence of ra-
diological vertebral deformities than non acromegalic
postmenopausal women (186). This can be explained
with an association between acromegaly and an in-
creased risk of osteoporotic vertebral fractures (180,
187) which is correlated with the duration of active dis-
ease and the serum level of IGF-I, whereas there is no
significant relationship between vertebral fractures
and BMD values in acromegalic patients (180, 187).
As concern the effects of acromegaly’s treatment on
bone metabolism, an improvement has been observed
in fractures and BMD after surgical treatment
(transphenoidal pituitary surgery) or pharmacological
therapy. However data about treatment and his influ-
ence on bone are limited (180). Some authors have
demonstrated that therapy with the GH antagonist
pegvisomant, a selective antagonist of the GHR,
which controls IGF-I secretion lead to a normalization
of bone turnover (180). A reduction has been demon-
strated in PTH target organ sensitivity and a reduced
nocturnal rise in PTH after the normalization of
GH/IGF-I levels (180). The hormonal control in post-
menopausal women lead to a reduction of risk of radi-
ological vertebral fractures than women with active
disease. These improvement is not correlated with
BMD value (180). In conclusion, the mechanisms un-
derlying the metabolic bone disease of acromegaly
are multifactorial and possibly include an increase in
bone resorption secondary to IGF-I excess and to sex
hormone deficiency.
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Postmenopausal and senile osteoporosis
The occurrence of postmenopausal osteoporosis is
about 35% of white women and 19% of white elderly
men (180). Among risk factors estrogen deficiency
plays a main role both in postmenopausal osteoporo-
sis and in possibly male osteoporosis (180). Second-
ary hyperparathyroidism, vitamin D deficiency, de-
creased IGF-I levels and a large number of other fac-
tors could lead to the bone loss, probably due to de-
crease of osteoblastic functions in elderly population
(180). A reduction of GH and IGF-I secretion, called
“somatopause”, has been demonstrated in advancing
age. This event could be implicated in the pathogene-
sis of osteoporosis (180). In fact some studies have
observed a reduction of serum IGF-I levels in post-
menopausal women which is correlated with BMD.
Moreover has been demonstrated that IGF-I promoter
polymorphisms have been linked to bone mass (180).
Both the serum IGF-I and the IGF-I contained in hu-
man cortical bone decrease with age (180). There are
different evidences about the effects of rh-GH in post-
menopausal female, males with idiopathic osteoporo-
sis and elderly patients. In these patients has been
observed an improvement of bone metabolism but the
effect of rhGH on BMD is controversial (180). Some
authors have observed a positive effect of rhGH treat-
ment on increase in BMD in osteoporotic patients, oth-
er authors have demonstrated any benefic effects al-
though an increase of serum IGF-I levels (180). In a
recent meta-analysis has been observed that older
people have not any improvement in bone metabolism
due to rh-GH treatment. This probably can be ex-
plained by the lack of controlled trials and the hetero-
geneity of the subjects examined (180). Recent stud-
ies have demonstrated that treatment with an orally
active GH secretagogue (MK677) combined with alen-
dronate can determinate an improvement of BMD on-
ly at femoral neck in postmenopausal osteoporosis
(180). Recombinant human IGF-I can influence bone
metabolism in humans, but there is no skeletal speci-
ficity and potential side effects which would limit its
possible use in osteoporosis (180).
Obesity and GH/IGF-I axis
It has been shown that nutritional state is an important
factor involved in the control of Growth Hormone (GH)
secretion. In human obesity, the GH/IGF-I axis is al-
tered at different levels. Basal GH secretion is blunted,
with reduced GH half-life, frequency of secretory
episodes and daily production rate and it has been re-
ported that an increase in each unit of BMI, at a given
age, reduces the daily GH secretion by 6% (188). GH
secretion is impaired in response to all stimuli acting
at the hypothalamus and to direct stimulation by ex-
ogenous GHRH (Growth Hormone Releasing Hor-
mone).The plasma levels of the high affinity GHBP
(Growth Hormone Binding Protein) are increased, with
a positive correlation between serum levels of this
molecule and both BMI and percent body fat mass.
The physiological significance of increased GHBP in
R. Baldelli et al.
24 Reviews in Endocrinology and Metabolism 2013; 1 (1): 11-33
obesity is unknown. Increased GHBP levels in obesity
may serve to prolong the biological activity of GH,
however various studies showed that the clearance of
GH is accelerated in obesity. Because circulating lev-
els of GHBP reflect GH receptor density, an alternative
explanation might be that the greater density of tissue
receptors acts to sequester GH more avidly from the
circulation, and this phenomenon might represent tis-
sue adaptation to reduced GH output in obesity. The
reduced GH response to GHRH in obese fasting pa-
tients seems to be caused by both central and periph-
eral factors. Among central factors, an impairment of
endogenous GHRH tone or an augmentated somato-
statin release has been hypotesized. It has been also
suggested that the defect resides in the pituitary
gland, with enhanced somatostatin release being re-
sponsible for the blunted GH response. However,
many experimental evidences confirmed that both
GHRH and somoatostatin release are normal in obesi-
ty and that there isn’t a somatotrope cell insufficiency,
since we observe a great GHRH and GH-releasing
peptide-6 induced GH release in obese subjects
(189). In obesity, GH secretion is blunted in response
to other stimuli acting at the hypothalamus (insulin-in-
duced hypoglycemia, arginine, galanin, L-dopa, cloni-
dine) and the pharmacological manipulation of the
central neurotransmitter systems are capable of mod-
ifying, but not completely restore, the response to
these stimuli. Amongst the peripheral factors, the role
of the increased bioavaibility of IGF-1, measured by
IGF-1/IGFBP-3 ratio, and their possible increased
negative feedback action on somatotroph cells has
been underlined in some studies. However, in obesity,
IGF-I plasmatic levels could be normal, low or high,
despite high serum levels of the free fraction of IGF-I.
Free IGF-I accounts for less than 1% of the total circu-
lating amount of IGF-I and it is believed to be respon-
sible for the bioactivity on target tissue. Two recent
study (190, 191) indicated that free IGF-I are signifi-
cant increased in overweight and obese patients;
therefore, it seems not correct to define obesity a con-
dition of GH resistence or insensitivity. Finally, accord-
ing to the presence of increased levels of free IGF-I, in
obesity IGFBP-1 (Insulin-like Growth Factor Binding
Protein-1) and -BP-2 plasma levels are blunted, due to
inhibition by insulin, which is generally increased in
overweight subjects, whereas IGFBP-3 levels are nor-
mal or high. On the other hand, some authors have
shown that low IGF-I levels are inversely correlated
with abdominal obesity, a condition associated with
higher serum concentrations of non-esterifed fatty
acids (NEFA). The mechanism of this clinical evidence
is not well known. We know that adipose tissue is a
relevant source of proinflammatory cytokines and re-
cent data suggest that inflammatory mediators may
play a role in inducing reduced IGF-I bioactivity (192).
The question of whether these mediators play a role in
the IGF-I/IGF-binding protein system in obesity re-
quires future study. Insulin and NEFA (or Free Fatty
Acids, FFA) levels seem to be the most important pe-
ripheral factors involved in the blunted GH levels in
obesity. Experimental and clinical data support the ex-
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istence of a negative feedback exerted by circulating
insulin on GH secretion. Insulin is able to reduce GH
release from rat pituitary in vitro, suggesting an IGF-I-
like effect, and it may be a major determinant in the
suppression of GH output in the obese mouse by di-
rect down-regulation of somatotrope function at pitu-
itary level (193). Massive weight loss, inducing a de-
crease of insulin secretion, seems to be directly in-
volved in the restore of a normal 24 h GH profile (194).
The surgical treatment of severe obesity, after stabi-
lization of body weight, decreases body mass index
(BMI) and fatt mass (FM) while preserving a normal
lean body mass (LBM) as well as positively influencing
insulin sensitivity. An interesting study in this field
showed that in morbid obesity, after biliopancreatic di-
version, the decrease in insulin secretion is the start-
ing point for the changes in both body composition
changes and somatotrope axis (195). In the same di-
rection, recently, Cornford et al., showed a strong sup-
pressed GH secretion in seven healthy non-obese
men, after only 2 weeks of overeating and before any
measurable weight gain; this phenomenon was ac-
companied only by a significant increase in insulin
plasma levels, the likely mediator of the reduction in
GH secretion (191). The direct infusion of FFA in nor-
mal weight subjects completely inhibits GH secretion.
Several lines of experimental evidence indicate that
high circulating FFA play an important role in the im-
pairment of spontaneous and stimulated GH secretion
in obesity, given the improvement of somatotropin re-
lease observed in obese patients after the administra-
tion of the antilipolytic agent acipimox (196). In such
models such as PCO or old normal subjects, where
the GH response to GHRH is similar to that in obese
subjects, it has been shown how a pharmaceutical de-
crease in FFA levels can re-establish a normal GH re-
sponse. However, the majority of these studies indi-
cate that FFA reduction does not directly stimulate GH
secretion, but augments the action of other stimuli at
hypothalamus-pituitary level. The encouraging effects
of GH in the treatment of Growth Hormone deficiency
(GHD) syndrome have generated interest in the effica-
cy of using GH as anti-obesity drug. The rational of
this treatment is firstly the observed lipolitic affect, es-
pecially on abdominal body fat, and the concomitant
anabolic action related to growth of lean body mass.
Conversely, the insulin-resistance, the impaired glu-
cose metabolism, the onset of water retention, edema,
carpal tunnel syndrome, arthralgia are the main dose-
related side effects of GH therapy. The dose of GH
more efficacious in obesity, and without side effects,
was in the range of the current dose of GHD treat-
ment, or slightly more low. The studies present in liter-
ature showed no significant effects of GH administra-
tion on BMI or LBM, independently from duration of
treatment. In the majority of cases, a significant reduc-
tion in visceral adipose tissue, ranging from 5% to
34% was observed, mainly in the clinical trial of at
least 12 weeks of duration (197). In comparison, ther-
apeutic programs, with caloric restriction, diet and
physical exercise achieve the same results regarding
the fat mass. In conclusion, in obesity a clear de-
Uptodate on GH/IGF-1 axis actions
Reviews in Endocrinology and Metabolism 2013; 1 (1): 11-33 25
crease in GH secretion with normal, high or low IGF-I,
but high free IGF-I is observed. This condition is re-
versible and it seems to originate from peripheral fac-
tors, which alter hypothalamic-pituitary function. The
restoration of normal GH/IGF-I axis function after
weight loss suggests the presence of an acquired de-
fect of metabolic origin. Clinical studies on the effica-
cy of rhGH as antiobesity drugs does haven’t shown
results in terms of weight loss significantly larger than
those achievable with only diet-therapy. The observed
effects of rhGH on body composition changes, with
particular reference to reduction of abdominal and to-
tal fat mass are encouraging, but long term studies are
nedeed. 
GH/IGF-I axis and lymphohematopoietic system
Important evidences show existence of a relationship
between neuroendocrine and immune systems. Pep-
tides exert effects in a cytokines like manner on im-
mune, lymphoid and red blood cells. Production and
differentiation of forerunners of red blood cells,
myeloid and lymphoid cells are under cytokines, pep-
tides and hormones control (198). In respect of hor-
mones’ actions, Growth hormone (GH) and its proxi-
mal mediator insulin-like growth factor-I (IGF-I) have
been shown to play an important role. GH acts direct-
ly through interaction on GH receptors (that is a cy-
tokine receptor class 1) or indirectly through the IGF-I
share. IGF-I shows both proliferative and anti apopto-
sis action (joint with receptors of Tyrosine kinase in-
volved in the intracellular signalling of PI3K and anti
apoptosis protein Bcl2). The presence of GH- and
IGF-I- receptors on B and T lymphoid cells, monocytes
macrophages, fibroblasts and neutrophylis suggest
the possibility of an immune action in association with
the principal endocrine activity (199). In the bone mar-
row and in the thymus IGF-I is capable to promote the
survival of forerunners blood cells and to prevent
apoptosis (through way of PI3K). GH deficit causes
subclinical changes in the chemotaxis and in the
phagocytosis of granulocytes and macrophages.
Moreover patients affected by GH deficit have a re-
duction of 50% in the function of natural killer cells,
CD3- and CD56+. GH deficiency is often associated
with a higher frequency of infectious, autoimmunity
disorders and allergy. Furthermore the activity of nat-
ural killer cells improves after three-months of replace-
ment therapy with recombinant human GH (rhGH),
and normalizes after six-nine month of rh-GH replace-
ment treatment. The functionality of phagocytes and
neutrophilis improves after a long period of rh-GH
therapy too. In humans the important role of GH/IGF-I
axis has been underline, also, by in vivo study. Pa-
tients affected by GH deficiency show many immune
changes like reduced functionality of NK, insufficient
antibody synthesis, thymus atrophy and changes of
immune response mediate by immune cells. GH deficit
is associate with increased prevalence of atheroscle-
rosis and, consequently, higher morbidity and mortali-
ty for cardiovascular events. Different trials have as-
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sessed a possible role of GH deficit and its recombi-
nant replacement therapy on the monocytes’s activa-
tion. In fact GH caused chemotaxis of monocytes, pro-
duction of oxygen’s radicals by macrophages and
manage the TNFα expression. Monocytes play an im-
portant role in the development of the atherogenic
plaque. In GH deficiency there is a damage in
macrophages’ functions: in bloodstream the capacity
to adhere tightly to endothelial cells is increased by
cytokines like IL-6 and TNF-α, markers of monocytes
activation at the beginning of atherosclerosis’ process.
Others studies showed a relationship between GH
deficit, anaemia and blood platelet reduction. GH re-
placement therapy improved concentration of haemo-
globin, improved the myeloid activity and also in-
creased secretion of cytokines like TNFα and IL-6. On
the other side, in patients affected by high levels of
GH, like in acromegaly, a condition of clear poly-
cythemia, reversible by surgical or medical therapy,
could be observed. Lastly we can observe a reduction
in the function of GH/IGF-I axis in elderly, catabolic
conditions, important illness and where there is status
of resistance. GH resistance syndrome is character-
ized by moderate increase of GH levels, high levels of
IGFBP-1 and IGFBP-2 and reduction of IGF-I, IGF-II
and IGFBP-3. Moreover there is a reduced capacity of
IGFBP-3 to work and create complex (more of 90% of
IGF-I in bloodstream is bound at complex with IGFBP-
3; IGF-I have anabolic effect and this one is higher
when is bound in this complex) and so there is further
reduction of IGF-I and IGF-II levels in bloodstream
and changes in their biological activity. In elderly peo-
ple changes of GH/IGF-I axis could be responsible for
an increase in abdominal adiposity, a greater risk of
cardiovascular mortality, and a depressed level of
wellness. Immune senescence is associated with
wasting thymus and reduction in oligoclonal T cells re-
ceptor. Older people are more susceptible of infec-
tions and show a reduction of immune answer to vac-
cines. In the future rhGH therapy could be a new
chance to restore thymus functionality, to reduce age
related changes and improve immune control against
cancer and infections (199). Another important new
therapeutic option for GH therapy could be in patients
affected by HIV infection. GH/IGF-I axis functionality is
important in protein synthesis and to preserve normal
muscular mass. GH and IGF-I could increase the re-
tention of nitrogenous and induce protein synthesis
(200). Moreover, in some cases, GH/IGF-I function
could have an important role in the nutritional status
and body composition which are impaired in HIV in-
fected patients. HIV infection produces an unspecific
clinical status similar to many others endocrine and
non endocrine illness while antiretroviral therapy
causes endocrine malfunction too. Moreover in pa-
tients with AIDS it could be observed an important
cachexia. AIDS-related cachexia is characterized by a
reduced muscular mass for changes in metabolism
and by a status of resistance to GH (201). IL-6 and
TNF-α causes IGF-I resistance, directly related to the
gravity of infection phase. There is a relation between
GH/IGF-I axis and progression of illness (for example
R. Baldelli et al.
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reduction of number of CD4 lymphoid cells, weight
loss and re-allocation of adipose tissue). Moreover pa-
tients with reduced rate of CD4 helper show high lev-
els of IGFBP-1, distinctive trait of catabolic status.
Moreover TNF-α enhances levels of IGFBP-1 and its
liver production. IGFBP-2 is significantly represented
in the HIV patients before beginning of AIDS. Patients
with AIDS-related cachexia show dramatic reduction
of IGF-I, IGF-II and IGFBP-3 levels when more than
10% of body mass is lost. Replacement therapy with
rhGH could increases levels of red blood cells and im-
proves physical performance increasing enzymatic ox-
idative activity of skeletal muscles. rhGH replacement
therapy increases IGF-I levels and is responsible for
an higher muscular oxidative activity in AIDS-related
cachexia. In this respect GH could be a new approach
to improve clinical status in patients with HIV infection
(202, 203). Also the various processes involved in HIV
lipodystrophy result in the suppression of pituitary GH
production. The GHRH analog Tesamorelin is the only
treatment wich is FDA approved for reduction excess
abdominal fat in HIV lipodystrophy (204).
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